Industries > Pharma > Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

PUBLISHED: 17 December 2018
PAGES: 232
PRODUCT CODE: PHA0345
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0345 Categories: , Tags: , , , ,

The global rheumatoid arthritis drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 232-page report you will receive 234 charts– all unavailable elsewhere.

The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Rheumatoid Arthritis Market from 2019-2029

• Forecast of the Global Rheumatoid Arthritis market by Submarket:
• Biologics
• Non-Biologics: NSAIDs, sDMARDs and Others

• Forecast of the leading drugs in the Global Rheumatoid Arthritis market:
• Humira
• Enbrel
• Remicade
• Rituxan/MabThera
• Simponi/Simponi Aria
• Orencia
• Actemra/Roactemra
• Cimzia
• Celebrex
• Xeljanz
• Arcoxia
• Others

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia and rest of Europe
• Asia-Pacific: Japan, China, India and rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

• Our study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:
• AbbVie
• Amgen
• AstraZeneca
• BMS
• Eli Lilly
• Johnson & Johnson
• Merck & Co
• Novartis
• Pfizer
• Roche
• Sanofi
• UCB

• Our study discusses selected compounds under development for rheumatoid arthritis.

• This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.

Buy our report today Global Rheumatoid Arthritis Drugs Market Analysis : Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories